Should Oncologists Recommend Cannabis?
Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially approved for the treatment of chemotherapy-related nausea and vomiting in 1986. The indication was expanded in 1992 to include treatment of anorexia in patients with the AIDS wasting syndrome. Hence, if the dominant cannabinoid is available as a schedule III prescription medication, it would seem logical that the parent botanical would likely have similar therapeutic benefits. The system of cannabinoid receptors and endogenous cannabinoids (endocannabinoids) has likely developed to help us modulate our response to noxious stimuli. Phytocannabinoids also complex with these receptors, and the analgesic effects of cannabis are perhaps the best supported by clinical evidence. Cannabis and its constituents have also been reported to be useful in assisting with sleep, mood, and anxiety. Despite significant in vitro and animal model evidence supporting the anti-cancer activity of individual cannabinoids—particularly THC and cannabidiol (CBD)—clinical evidence is absent. A single intervention that can assist with nausea, appetite, pain, mood, and sleep is certainly a valuable addition to the palliative care armamentarium. Although many healthcare providers advise against the inhalation of a botanical as a twenty-first century drug-delivery system, evidence for serious harmful effects of cannabis inhalation is scant and a variety of other methods of ingestion are currently available from dispensaries in locales where patients have access to medicinal cannabis. Oncologists and palliative care providers should recommend this botanical remedy to their patients to gain first-hand evidence of its therapeutic potential despite the paucity of results from randomized placebo-controlled clinical trials to appreciate that it is both safe and effective and really does not require a package insert.
KeywordsCannabis Medical marijuana Delta-9-tetrahydrocannabinol (THC) Cannabidiol (CBD) Symptom management Nausea and vomiting Anorexia Pain Synergy with opiates Sleep Insomnia Anxiety Antitumor activity
Compliance with Ethical Standards
Conflict of Interest
Donald I. Abrams has received compensation from AXIM Biotechnologies, Insys Therapeutics, Intec, Maui Grown Therapies, Scriptyx, Spectrum, Tikun Olam, and VIVO Cannabis for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq. Accessed 24 May 1999. A continuously updated summary of the published literature on cannabinoids in cancer care.
- 5.•• National Academies of Sciences, Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017. The latest review and analysis of the health effects as gleaned from recently published peer-reviewed articles with weight of evidence scoring.Google Scholar
- 9.Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;12(11):CD009464Google Scholar
- 11.Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016;(2):CD007786.Google Scholar
- 14.Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167–79.Google Scholar
- 16.Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46(2):207–18.Google Scholar
- 17.Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179–88.Google Scholar
- 18.• Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017;123(22):4488–97 Excellent overview of cannabis use by cancer patients at a comprehensive cancer center in a state where recreational cannabis is available.PubMedPubMedCentralGoogle Scholar
- 19.• Schleider LB, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;1(49):37–43 Information obtained from 2000 Israeli cancer patients using government licensed cannabis for symptom management.Google Scholar
- 20.•• https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html. Accessed 24 May 1999. An updated comprehensive review of cannabis as medicine.
- 24.Turgeman I, Bar-Sela G. Cannabis use in palliative oncology: a review of the evidence for popular indications. In: International Conference on Medical Cannabis 2016Google Scholar
- 25.• Turgeman I, Bar-Sela G. Cannabis for cancer–illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 20 A comprehensive review of cannabis in cancer care.Google Scholar
- 26.• Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7–11 A concise summary of the main findings with regard to the therapeutic effects of cannabis as summarized in the National Academies of Sciences, Engineering and Medicine’s report.PubMedGoogle Scholar
- 37.•• Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259. An excellent summary and review of the use of cannabis in pain.Google Scholar
- 40.Aviram J, Samuelly-Leichtag G Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755–E796Google Scholar
- 44.Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manag. 2014;47(1):166–73.Google Scholar
- 49.Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff. 2016;35(7):1230–6.Google Scholar
- 51.• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9. A nice review of the different effects of inhaled versus ingested cannabis and other plant-related issues.Google Scholar
- 61.Rocha FC, dos Santos Júnior JG, Stefano SC, da Silveira DX. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neuro-Oncol. 2014;116(1):11–24.Google Scholar
- 68.• Ladin DA, Soliman E, Griffin L, Van Dross R. Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Front Pharmacol. 2016;7:361 Summary of the expression of cannabinoid receptors in various tumor types that may have implications for future treatment protocols.PubMedPubMedCentralGoogle Scholar
- 71.Wallace JM, Lim R, Browdy BL, Hopewell PC, Glassroth J, Rosen MJ, et al. Pulmonary Complications of HIV Infection Study Group. Risk factors and outcomes associated with identification of aspergillus in respiratory specimens from persons with HIV disease. Chest. 1998;114(1):131–7.PubMedGoogle Scholar
- 75.Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist. 2019;theoncologist-2018.18 31:1–2.Google Scholar
- 76.• Braun IM, Wright, Peteet J, Meyer FL, Yuppa DP, Bolcic-Jankovic D, et al. Medical oncologists’ beliefs, practices and knowledge regarding marijuana used therapeutically: a nationally representative survey study. J Clin Oncol. 2018;36:1957–62 Results of a survey of oncologists knowledge, attitudes and beliefs regarding cannabis in cancer patients and a call for more education on the topic.PubMedPubMedCentralGoogle Scholar